Month: September 2020

Sep 21 2020

Uncategorized

Pamela Turner shooting: Texas police officer indicted in death of woman with schizophrenia last year

by Clinical Editor

No Comments

A police officer has been indicted on charges of aggravated assault more than a year after fatally shooting a schizophrenic woman in Baytown, Texas, a Houston suburb. Baytown officer Juan...

Sep 21 2020

Uncategorized

Boehringer’s schizophrenia med boosts cognition in phase 2

by Clinical Editor

No Comments

Boehringer Ingelheim’s schizophrenia hopeful hit the mark in a phase 2 study, helping patients overcome cognitive impairment that can affect everyday tasks, such as remembering important dates or …

Sep 20 2020

Uncategorized

Yale Researchers to Lead $52M Investigation Into Cause, Effect of Schizophrenia in Some High-risk Adolescents – Yale School of Medicine

by Clinical Editor

No Comments

Yale Researchers to Lead $52M Investigation Into Cause, Effect of Schizophrenia in Some High-risk Adolescents  Yale School of Medicine

Sep 20 2020

Uncategorized

Researchers reveal sex differences in association between symptoms of schizophrenia and superoxide dismutase

by Clinical Editor

No Comments

Schizophrenia is a disabling psychiatric disorder characterized by positive symptoms, such as hallucinations and delusions, negative symptoms, such as decreased expression ability, and cognitive …

Sep 20 2020

Uncategorized

Pamela Turner shooting: Texas police officer indicted in death of woman with schizophrenia last year

by Clinical Editor

No Comments

A police officer has been indicted on charges of aggravated assault more than a year after fatally shooting a schizophrenic woman in Baytown, Texas, a Houston suburb. Baytown officer Juan...

Sep 20 2020

Uncategorized

NIH public-private partnership to advance early interventions for schizophrenia

by Clinical Editor

No Comments

Effort is part of the Accelerating Medicines Partnership to promote development of effective, targeted treatments.

Sep 20 2020

Uncategorized

Institute of Living research team selected to join international research effort studying schizophrenia in young people

by Clinical Editor

No Comments

A research team at the Institute of Living will join an international research effort studying schizophrenia in high-risk adolescents and young adults. About 3.2% to 7% of young people in...

Sep 20 2020

Uncategorized

Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia

by Clinical Editor

No Comments

Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint. The data showed improvement in cognition in …

Sep 19 2020

Uncategorized

Researchers reveal sex differences in association between symptoms of schizophrenia and superoxide dismutase

by Clinical Editor

No Comments

Schizophrenia is a disabling psychiatric disorder characterized by positive symptoms, such as hallucinations and delusions, negative symptoms, such as decreased expression ability, and cognitive …

Sep 19 2020

Uncategorized

NIH public-private partnership to advance early interventions for schizophrenia

by Clinical Editor

No Comments

Effort is part of the Accelerating Medicines Partnership to promote development of effective, targeted treatments.